Tetrathiomolybdate

Drug Profile

Tetrathiomolybdate

Alternative Names: ATN-224 analogue; Coprexa; TTM

Latest Information Update: 17 Feb 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Michigan
  • Developer Synthetic Biologics
  • Class Heavy metals; Small molecules
  • Mechanism of Action Amyloid beta-protein precursor inhibitors; Chelating agents; Fibroblast growth factor inhibitors; Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary fibrosis

Highest Development Phases

  • Suspended Alzheimer's disease; Hepatolenticular degeneration; Huntington's disease; Primary biliary cirrhosis; Pulmonary fibrosis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 16 Feb 2012 Adeona Pharmaceuticals is now called Synthetic Biologics
  • 02 Sep 2009 Adeona Pharmaceuticals is seeking partners for further development of Tetrathiomolybdate (http://www.adeonapharma.com/)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top